CN116783201A - 杂环酰胺衍生物及其制备方法和应用 - Google Patents
杂环酰胺衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116783201A CN116783201A CN202280012166.8A CN202280012166A CN116783201A CN 116783201 A CN116783201 A CN 116783201A CN 202280012166 A CN202280012166 A CN 202280012166A CN 116783201 A CN116783201 A CN 116783201A
- Authority
- CN
- China
- Prior art keywords
- group
- compound
- substituted
- unsubstituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- -1 Heterocyclic amide Chemical class 0.000 title abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 139
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 238000011321 prophylaxis Methods 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 239000012453 solvate Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 19
- 230000000155 isotopic effect Effects 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 38
- 108020003175 receptors Proteins 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 27
- 238000000034 method Methods 0.000 description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Chemical compound OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000002894 organic compounds Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- OCKVFWYEQXFJIN-UHFFFAOYSA-N 4-bromo-5-methyl-2,3-dihydrothiophene Chemical compound C1CC(=C(C)S1)Br OCKVFWYEQXFJIN-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101150109738 Ptger4 gene Proteins 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 2
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 150000001602 bicycloalkyls Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 2
- 125000005348 fluorocycloalkyl group Chemical group 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- WLBNVSIQCFHAQB-UHFFFAOYSA-N methyl 1h-pyrrole-3-carboxylate Chemical compound COC(=O)C=1C=CNC=1 WLBNVSIQCFHAQB-UHFFFAOYSA-N 0.000 description 2
- PBTHJVDBCFJQGG-UHFFFAOYSA-N methyl azide Chemical compound CN=[N+]=[N-] PBTHJVDBCFJQGG-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- RNHWYOLIEJIAMV-UHFFFAOYSA-N 1-chlorotetradecane Chemical class CCCCCCCCCCCCCCCl RNHWYOLIEJIAMV-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- QEVGZEDELICMKH-UHFFFAOYSA-L 2-(carboxylatomethoxy)acetate Chemical compound [O-]C(=O)COCC([O-])=O QEVGZEDELICMKH-UHFFFAOYSA-L 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- NXBRLTKLAXZRPO-UHFFFAOYSA-N 4-bromo-5-methylthiophene-2-carbaldehyde Chemical compound CC=1SC(C=O)=CC=1Br NXBRLTKLAXZRPO-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- BFHGXKUYFXAMOZ-UHFFFAOYSA-N [4-(bromomethyl)phenyl]-pentafluoro-$l^{6}-sulfane Chemical compound FS(F)(F)(F)(F)C1=CC=C(CBr)C=C1 BFHGXKUYFXAMOZ-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical class BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N deuterated acetone Substances [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000005345 deuteroalkyl group Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- VONGYFFEWFJHNP-UHFFFAOYSA-N methyl 1h-pyrrole-2-carboxylate Chemical compound COC(=O)C1=CC=CN1 VONGYFFEWFJHNP-UHFFFAOYSA-N 0.000 description 1
- JUMQWXLIAYMPHT-UHFFFAOYSA-N methyl 4-(1-aminocyclopropyl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1(N)CC1 JUMQWXLIAYMPHT-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种杂环酰胺衍生物及其制备方法和应用。具体地,涉及一种式I化合物及其制备方法和应用,包括所述化合物作为活性成分的药物组合物或其药学上可接受的盐。本发明进一步涉及式(I)化合物在用于治疗和预防EP4介导的疾病的用途。
Description
本发明属于医药化学领域,具体涉及一种杂环酰胺衍生物及其制备方法和应用。
前列腺素受体及其最常用的选择性激动剂和拮抗剂的特征和治疗实用性已被广泛地研究。前列腺素是引发疼痛、发烧和其他与炎症相关症状的介质。前列腺素E
2(PGE
2)是与炎症有关的花生酸主要代谢产物。此外,前列腺素E
2还参与各种生理和/或病理症状,如痛觉过敏、子宫收缩、消化道蠕动、觉醒、胃酸分泌的抑制、血压、血小板功能、骨代谢、血管生成等等。前列腺素E
2受体四个亚型(EP
1,EP
2,EP
3和EP
4)表现出不同的药理学特性。
EP
4受体的特征在于与其他前列腺素类受体相比时具有最长的细胞内C末端环。EP
4受体与G蛋白耦联,并介导环状单磷酸腺苷浓度升高。EP
4受体的表达受各种生理性和病理生理性过程控制,因为该受体参与排卵与受精、诱导骨形成、T细胞因子信号传导、预防炎症性肠病、促进朗格汉斯细胞迁移与成熟,并且在胶原诱导的关节炎模型中介导关节炎症以及其他过程。
研究表明,EP
4受体介导的cAMP水平升高是导致免疫细胞免疫抑制的主要信号。在APCmin突变的背景下,与野生动物相比,小鼠中EP4的敲除显示可延迟肿瘤的发生,表明宿主免疫细胞中PGE
2-EP
4信号传导的促肿瘤活性。
因此,本发明公开的化合物预计对治疗包括人类的哺乳动物由EP
4受体介导的疾病或不适有治疗作用,包括急性和慢性疼痛、骨关节炎、类风湿关节炎和癌症。
综上所述,本领域仍然迫切需要能够在体外和体内均有效且可靠地抑制EP
4的新型化合物。
发明内容
本发明的目的是提供一类新型的具有EP
4受体抑制活性和/或具有良好药效学/药代动力学性能的可作为EP
4受体拮抗剂的新颖化合物及其可药用盐,和以它们作为活性成分的药物组合物,以及其在治疗或减轻EP
4受体相关疾病如前列腺素EP
4受体介导的疾病中的用途。
本发明的第一方面,提供了一种式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药;
其中,
R
1独立地选自下组:氢、卤素、取代或未取代的C
1-6烷基、取代或未取代的C
3-6环烷基;
R
2和R
3各自独立选自下组:氢、取代或未取代的C
1-6烷基、取代或未取代的C
3-6环烷基;或者,R
2和R
3以及与其相连的碳原子共同构成C
3-6碳环或3至6元杂环;所述杂环包含一个或两个各独立选自S、O或NR
b的环成员;并且,所述C
3-6碳环或3至6元杂环任选地被一个或多个R
1取代;
R
b各自独立地选自下组:氢、取代或未取代的C
1-6烷基、取代或未取代的取代或未取代的C
3-6环烷基、取代或未取代的C
6-10芳基、取代或未取代的5至6元杂芳基、-C(O)R
c、-S(O)
2R
c;
R
c各自独立地选自下组:取代或未取代的C
1-6烷基、取代或未取代的C
3-6碳环、取代或未取代的3至6元杂环、取代或未取代的C
6-10芳基、取代或未取代的5至10元杂芳基;
R
4和R
5各自独立选自下组:氢、取代或未取代的C
1-3烷基;或者,R
4和R
5以及与其相连的碳原子共同构成取代或未取代的C
3-6碳环(如环丙基);
R
6代表无或选自下组的基团:卤素、氰基、卤代烷基(如三氟甲基);
除非特别说明,所述的取代是指基团中一个或多个(如1、2或3个)氢被选自下组的取代基所取代:卤素(如F)、C
1-4烷基、C
1-4卤代烷基。
在另一优选例中,所述取代或未取代的C
1-6烷基为C
1-6烷基或者C
1-6卤代烷基;较佳地,为C
1-6烷基或者C
1-6氟代烷基。
在另一优选例中,所述取代或未取代的C
3-6环烷基为C
3-6环烷基或者C
3-6卤代环烷基;较佳地,为C
3-6烷基或者C
3-6氟代环烷基。
在另一优选例中,R
1独立选自下组:氢、卤素、C
1-6烷基、C
3-6环烷基、C
3-6氟代环烷基、C
1-6氟代烷基;
R
2和R
3各自独立选自下组:氢、C
1-6烷基、C
3-6环烷基、C
3-6氟环烷基、C
1-6氟烷基;或者,R
2和R
3以及与其相连的碳原子共同构成C
3-6碳环或3至6元杂环;其中,所述杂环包含一个或两个各独立选自S、O或NR
b的环成员;并且,所述C
3-6碳环或3至6元杂环还任选地被R
1取代;
R
b选自下组:氢、C
1-6烷基、C
3-6环烷基、C
3-6氟环烷基、C
1-6氟烷基、C
6-10芳基、5至10元杂芳基、C(O)-C
1-6烷基、C(O)-C
6-10芳基、S(O)
2-C
1-6烷基、S(O)
2-C
6-10芳基;
R
4和R
5各自独立为氢或C
1-3烷基;
R
6代表无或选自下组的取代基:卤素、氰基、三氟甲基。
在另一优选例中,R
1选自下组:氢、卤素、C
1-6烷基、C
3-6环烷基;
在另一优选例中,R
2和R
3各自独立地选自氢、C
1-6烷基,或者,R
2和R
3以及与其相连的碳原子共同构成环丙基。
在另一优选例中,R
4和R
5各自独立地为氢或甲基。
在另一优选例中,R
6不为无时,R
6位于-SF
5的邻位或间位。
在另一优选例中,R
6代表无或选自下组的取代基:卤素。
在另一优选例中,R
1、R
2、R
3、R
4、R
5、R
6、R
b和R
c各自独立地为实施例化合物(如表1中所列出的化合物)中对应的基团。
在另一优选例中,所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,所述化合物选自下组:
在本发明的第二方面中,提供一种药物组合物,其包含如第一方面所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,以及药学上可接受的载体或稀释剂。
在本发明的第三方面中,提供了一种如第一方面所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药或如第二方面所述的药物组合物在制备(i)用于抑制EP
4受体活性的药物和/或(ii)用于治 疗或预防与EP
4受体相关疾病的药物和/或(iii)EP
4受体拮抗剂中的用途。
在另一优选例中,所述EP
4受体相关疾病包括前列腺素E2和/或前列腺素EP
4受体介导的疾病。
在另一优选例中,所述EP
4受体相关疾病包括:急性和慢性疼痛、骨关节炎、类风湿关节炎、癌症,或其组合。
在本发明的第四方面中,提供了一种治疗或预防EP
4受体相关疾病的方法,所述方法包括给予有需要的受试者治疗有效量的如第一方面所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,或如第二方面所述的药物组合物。
在另一优选例中,有需要的受试者是指被鉴定或诊断为具有EP
4受体相关疾病的受试者。
在本发明的第五方面中,提供了一种用于抑制细胞或受试者中的EP
4受体活性的方法,所述方法包括使所述细胞接触或向所述受试者施用第一方面所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药或第二方面所述的药物组合物的步骤。
在另一优选例中,所述细胞为哺乳动物细胞。
在另一优选例中,当所述方法用于抑制细胞时,所述方法是体外非治疗性的。
在另一优选例中,所述受试者为哺乳动物,优选为人。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
本发明人经过广泛而深入的研究,意外地发现了一类具有较好的EP
4受体抑制活性的具有新颖结构的化合物。此外,发明人还发现这些具有新颖结构的化合物具有良好药效学/药代动力学性能。在此基础上,完成了本发明。
术语
在本发明中,除非特别指出,所用术语具有本领域技术人员公知的一般含义。
当通过从左向右书写的常规化学式描述取代基时,该取代基也同样包括从 右向左书写结构式时所得到的在化学上等同的取代基。举例而言,-CH
2O-等同于-OCH
2-。
如本文所用,术语“烷基”本身或作为另一取代基的一部分,是指具有指定的碳原子数的直链或支链烃基(即,C
1-6是指一个至六个碳原子)。优选地,烷基一般包含1-6个碳原子,即C
1-
6烷基。烷基的实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、仲丁基、正戊基、正己基及其类似烷基。烷基中的一个或多个(如1-4个)位置可任选地被取代,所述的取代可在基团中的任何位置上进行。
如本文所用,术语“卤代烷基”指包括具有指定碳原子数且取代有1个或多个卤素的支链和直链饱和脂族烃基团。卤代烷基的实例包括但不限于氟甲基、二氟甲基、三氟甲基、三氯甲基、五氟乙基、五氯乙基、2,2,2-三氟乙基、七氟丙基和七氯丙基。卤代烷基的实例还包括具有指定碳原子数且取代有1个或多个氟原子的支链和直链饱和脂族烃基团的“氟烷基”。
术语“氟烷基”或“氟代烷基”是指上述定义的烷基,其中一个或多个氢原子被氟原子取代。
术语“烷氧基”是指通过醚氧连接的直链或支链或环状烷基,其游离价键来自该醚氧。代表性的例子包括(但并不限于):甲氧基、乙氧基、丙氧基、异丙氧基和丁氧基等。优选为C
1-3烷氧基。
术语“氟烷氧基”或“氟代烷氧基”是指如上定义的烷氧基,其中一个或多个氢原子被氟原子取代。
术语“卤代烷氧基”是指-O-卤代烷基,包括直链或支链或环状卤代烷氧基,代表性的例子包括(但并不限于):氟甲氧基、二氟甲氧基、三氟甲氧基、三氯甲氧基、五氟乙氧基、五氯乙氧基。
术语“环烷基”或“碳环”是指包括饱和单环、双环或多环的环状烷基,例如C
3-8或C
3-12环烷基。C
3-8环烷基指包括C
3、C
4、C
5、C
6、C
7、或C
8环烷基。环烷基还可包括螺环、桥环、并环等结构的环烷基。本发明的代表性的环烷基包括但不限于:环丙基、环丁基、环戊基、环己基和降莰烷基。应理解,取代或未取代的环烷基,例如支化环烷基(如1-甲基环丙基和2-甲基环丙基),均包括在“环烷基”的定义中。C
5-12稠合双环指包括C
5、C
6、C
7、C
8、C
9、C
10、C
11、C
12双环烷基,其包括但不限于:
等。C
5-12螺双环指包括C
5、 C
6、C
7、C
8、C
9、C
10、C
11、C
12双环烷基,其包括但不限于:
等。在本发明中,环烷基优选为含有3至6个碳原子(即C
3-6)的单环环烷基,如环丙基、环丁基、环戊基、或环己基。
术语“芳基”或“芳香基”,单独或作为诸如“芳烷基”、“芳烷氧基”或“芳基氧基烷基”基团中的部分,是指具有总计5至15个环成员(或环原子)的单环、二环或三环的环系统(优选6-10元芳环),其中所述系统中的至少一个环为芳族的且其中所述系统中的每个环含有3至7个环成员。“芳基”可以是取代的或者未取代的。在本发明的某些实施方案中,“芳基”是指芳族环系统,其包括但不限于苯基、联苯基、茚满基、1-萘基、2-萘基和四氢萘基。稠合的芳基可在环烷基环或芳族环的合适位置上连接至另一基团。从环系统中画出的连接线表明键可连接至任意合适的环原子。
术语“杂芳基”或“杂环芳香基”是指包含1-4个杂原子、5-14个环原子的杂芳族体系,其中杂原子选自氧、氮和硫。杂芳基优选5至10元环,更优选为5元或6元,例如吡咯基、吡唑基、咪唑基、噁唑基、异噁唑基、噻唑基、噻二唑基、异噻唑基、呋喃基、吡啶基、吡嗪基、嘧啶基、哒嗪基、三氮嗪基、三氮唑基及四氮唑基等。“杂芳基”可以是取代的或者未取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、烯基、炔基、烷硫基、烷基氨基、卤素、氨基、硝基、羟基、巯基、氰基、环烷基、杂环基、芳基、杂芳基、环烷硫基、氧代基、羧基和羧酸酯基。
术语“杂环烷基”或“杂环”是指含有一至五个选自N、O和S的杂原子的环烷基,其中氮和硫原子任选被氧化,且氮原子任选被季铵化。杂环烷基可以是单环、双环或多环体系。杂环烷基的非限制性例子包括吡咯烷、咪唑烷、吡唑烷、丁内酰胺、戊内酰胺、咪唑烷酮、乙内酰脲、二氧戊环、苯邻二甲酰亚胺、哌啶、1,4-二噁烷、吗啉、硫代吗啉、硫代吗啉-S-氧化物、硫代吗啉-S,S-氧化物、哌嗪、吡喃、吡啶酮、3-吡咯啉、噻喃、吡喃酮、四氢呋喃、四氢噻吩、奎宁环等。杂环烷基可以经环碳或杂原子连接于分子的其余部分。
术语“羟基”指-OH。
术语“硝基”指-NO
2。
术语“氨基”指-NH
2。
术语“卤代”或“卤素”包括氟、氯、溴和碘。
术语“氰基”指-CN。
在本发明中,上述的烷基、卤代烷基、芳基、杂芳基、烯基、炔基等中各基团 可以是取代的或未取代的。
在本发明中,术语“取代”指特定的基团上的一个或多个氢原子被特定的取代基所取代。特定的取代基为在前文中相应描述的取代基,或各实施例中所出现的取代基。除非特别说明,某个取代的基团可以在该基团的任何可取代的位点上具有一个选自特定组的取代基,所述的取代基在各个位置上可以是相同或不同的。本领域技术人员应理解,本发明所预期的取代基的组合是那些稳定的或化学上可实现的组合。典型的取代包括但不限于一个或多个以下基团:如氢、氘、卤素(例如,单卤素取代基或多卤素取代基,后者如三氟甲基或包含Cl
3的烷基)、腈基、硝基、氧代(如=O)、三氟甲基、三氟甲氧基、环烷基、烯基、炔基、杂环、芳环、OR
a、SR
a、S(=O)R
e、S(=O)
2R
e、P(=O)
2R
e、S(=O)
2OR
e,P(=O)
2OR
e、NR
bR
c、NR
bS(=O)
2R
e、NR
bP(=O)
2R
e、S(=O)
2NR
bR
c、P(=O)
2NR
bR
c、C(=O)OR
d、C(=O)R
a、C(=O)NR
bR
c、OC(=O)R
a、OC(=O)NR
bR
c、NR
bC(=O)OR
e、NR
dC(=O)NR
bR
c、NR
dS(=O)
2NR
bR
c、NR
dP(=O)
2NR
bR
c、NR
bC(=O)R
a、或NR
bP(=O)
2R
e,其中,R
a可以独立表示氢、氘、烷基、环烷基、烯基、炔基、杂环或芳环,R
b、R
c和R
d可以独立表示氢、氘、烷基、环烷基、杂环或芳环,或者R
b和R
c与N原子一起可以形成杂环;R
e可以独立表示氢、烷基、环烷基、烯基、炔基、杂环或芳环。上述典型的取代基,如烷基、环烷基、烯基、环烯基、炔基、杂环或芳环可以任选取代。所述取代基例如(但并不限于):卤素、羟基、氰基、羧基(-COOH)、C
1-6烷基、C
2-6烯基、C
2-6炔基、C
3-8环烷基、3-12元杂环基、芳基、杂芳基、C
1-8醛基、C
2-10酰基、C
2-10酯基、胺基、C
1-6烷氧基、C
1-10磺酰基、及C
1-6脲基等。
除非另外说明,假定任何不满价态的杂原子有足够的氢原子补充其价态。
当取代基为非末端取代基时,其为相应基团的亚基,例如烷基对应于亚烷基、环烷基对应亚环烷基、杂环基对亚杂环基、烷氧基对应亚烷氧基等。
术语“EP
4拮抗剂”是指抑制或阻断由PGE
2与EP
4受体的相互作用触发的细胞信号转导的化合物,包括但不限于本文所述的式(I)所示的化合物。
术语“治疗(treatment)”是指减轻,抑制和/或逆转需要其的受试者的癌症进展。术语“治疗”包括成功治疗或改善癌症的任何指标,包括任何客观或主观参数,例如减少;缓解;减轻症状或使受试者更耐受伤害、病理或病证;延缓或减缓进展速度等。治疗或改善的测量可以基于,例如,本领域已知的身体检查,病理学检查和/或诊断检查的结果。与在没有采取措施的情况下发生的情况相比,治疗还可以指减少癌症的发生或发作,或其复发(例如缓解时间的延长)。
术语“癌症”可以包括基因遗传突变的结果的癌症。这类癌症的例子包括但不限于乳腺癌,与李-弗劳梅尼综合症有关的癌症,例如儿童肉瘤,白血病和脑癌,与林奇综合症有关的癌症,例如结肠癌,胆管癌,脑癌,子宫内膜癌,肾癌,卵巢癌,胰腺癌,小肠癌,胃癌和输尿管癌,肺癌,黑素瘤,前列腺癌,成视网膜细胞瘤,甲状腺癌和子宫癌。此外,癌症可以是获得性突变的结果,例如,饮食,环境和/或生活方式引起的突变或体细胞突变。此类癌症的实例可包括但不限于肾上腺癌,肾上腺皮质癌,膀胱癌,脑癌,原发性脑癌,神经胶质瘤,成胶质细胞瘤,乳腺癌,宫颈癌,结肠癌(非限制性实例包括结直肠癌如结肠腺癌和结肠癌),子宫内膜癌,表皮癌,食道癌,胆囊癌,泌尿生殖道癌,头颈癌,肾癌,肝癌,肺癌(非限制性例子包括腺癌,小细胞肺癌和非小细胞肺癌),淋巴瘤(非限制性例子包括B细胞淋巴瘤,T细胞淋巴瘤,霍奇金淋巴瘤,非霍奇金淋巴瘤),黑素瘤,恶性黑素瘤,恶性类癌,恶性胰腺胰岛素瘤,骨髓瘤,多发性骨髓瘤,卵巢癌,胰腺癌(例如外分泌胰腺癌),前列腺癌,肾细胞癌,皮肤癌,例如,除前述的其它那些之外,鳞状细胞癌,胃癌,睾丸癌,甲状腺癌,甲状腺滤泡癌,威尔姆斯氏肿瘤,绒毛膜癌,霉菌病,恶性高钙血症,子宫颈增生,白血病,急性淋巴细胞性白血病,慢性淋巴细胞性白血病,毛细胞淋巴瘤,伯克氏淋巴瘤,急性粒细胞性白血病,慢性粒细胞性白血病,骨髓增生异常综合征,早幼粒细胞性白血病,慢性粒细胞白血病,急性粒细胞白血病,纤维肉瘤,横纹肌肉瘤(habdomyosarcoma),星形细胞瘤,神经母细胞瘤,横纹肌肉瘤(rhabdomyosarcoma),神经鞘瘤,卡波济肉瘤,多发性红细胞增多症,原发性血小板增多症,霍奇金病,非霍奇金淋巴瘤,软组织肉瘤,成骨肉瘤,原发性巨球蛋白血症,精原细胞瘤,畸胎瘤,骨肉瘤,异种皮色素瘤,角化角膜瘤和视网膜母细胞瘤。
活性成分
如本文所用,术语“本发明的化合物”或“本发明的活性成分”可互换使用,指式I化合物、或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物(如氘代化合物)或前药。该术语还包括外消旋体、光学异构体。
本发明化合物具有式I所示的结构
其中,R
1、R
2、R
3、R
4、R
5和R
6、R
b、R
c如前定义。
本发明中,化合物可能形成的盐也是属于本发明的范围。除非另有说明,本发明的化合物被理解为包括其盐类。在此使用的术语“盐”,指用无机或有机酸和碱形成酸式或碱式的盐。此外,当本发明中的化合物含一个碱性片段时,它包括但不限于吡啶或咪唑,含一个酸性片段时,包括但不限于羧酸,可能形成的两性离子(“内盐”)包含在术语“盐”的范围内。药学上可接受的(即无毒,生理可接受的)盐是首选,虽然其他盐类也有用,例如可以用在制备过程中的分离或纯化步骤。本发明的化合物可能形成盐,例如,化合物I与一定量如等当量的酸或碱反应,在介质中盐析出来,或在水溶液中冷冻干燥得来。
本发明的化合物含有的碱性片段或部分,包括但不限于胺或吡啶或咪唑环,可能会和有机或无机酸形成盐。可以成盐的典型的酸包括醋酸盐(如用醋酸或三卤代醋酸,如三氟乙酸)、己二酸盐、藻朊酸盐、抗坏血酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、硫酸氢盐、硼酸盐、丁酸盐、柠檬酸盐、樟脑盐、樟脑磺酸盐、环戊烷丙酸盐、二甘醇酸盐、十二烷基硫酸盐、乙烷磺酸盐、延胡索酸盐、葡庚糖酸盐、甘油磷酸盐、半硫酸盐、庚酸盐、己酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、羟基乙磺酸盐(如,2-羟基乙磺酸盐)、乳酸盐、马来酸盐、甲磺酸盐、萘磺酸盐(如,2-萘磺酸盐)、烟酸盐、硝酸盐、草酸盐、果胶酸盐、过硫酸盐、苯丙酸盐(如3-苯丙酸盐)、磷酸盐、苦味酸盐、新戊酸盐、丙酸盐,水杨酸盐、琥珀酸盐、硫酸盐(如与硫酸形成的)、磺酸盐、酒石酸盐、硫氰酸盐、甲苯磺酸盐如对甲苯磺酸盐、十二烷酸盐等等。
本发明的某些化合物可能含有的酸性片段或部分,包括但不限于羧酸,可能会和各种有机或无机碱形成盐。典型的碱形成的盐包括铵盐、碱金属盐如钠、锂、钾盐,碱土金属盐如钙、镁盐和有机碱形成的盐(如有机胺),如苄星、二环已基胺、海巴胺(与N,N-二(去氢枞基)乙二胺形成的盐)、N-甲基-D-葡糖胺、N-甲基-D-葡糖酰胺、叔丁基胺,以及和氨基酸如精氨酸、赖氨酸等等形成的盐。碱性含氮基团可以与卤化物季铵盐,如小分子烷基卤化物(如甲基、乙基、丙基和丁基的氯化物、溴 化物及碘化物),二烷基硫酸盐(如,硫酸二甲酯、二乙酯,二丁酯和二戊酯),长链卤化物(如癸基、十二烷基、十四烷基和十四烷基的氯化物、溴化物及碘化物),芳烷基卤化物(如苄基和苯基溴化物)等等。
本发明中化合物的前药及溶剂合物也在涵盖的范围之内。此处术语“前药”是指一种化合物,在治疗相关疾病时,经过代谢或化学过程的化学转化而产生本发明中的化合物、盐、或溶剂合物。本发明的化合物包括溶剂合物,如水合物。如本文所用,术语“溶剂合物”是指本发明化合物与溶剂分子配位形成特定比例的配合物。如本文所用,术语“水合物”是指本发明化合物与水进行配位形成的配合物,如一水合物。
本发明中的化合物、盐或溶剂合物,可能存在的互变异构形式(例如酰胺和亚胺醚)。所有这些互变异构体都是本发明的一部分。
所有化合物的立体异构体(例如,那些由于对各种取代可能存在的不对称碳原子),包括其对映体形式和非对映形式,都属于本发明的设想范围。本发明中的化合物独立的立体异构体可能不与其他异构体同时存在(例如,作为一个纯的或者实质上是纯的光学异构体具有特殊的活性),或者也可能是混合物,如消旋体,或与所有其他立体异构体或其中的一部分形成的混合物。本发明的手性中心有S或R两种构型,由理论与应用化学国际联合会(IUPAC)1974年建议定义。外消旋形式可通过物理方法解决,例如分步结晶,或通过衍生为非对映异构体分离结晶,或通过手性柱色谱法分离。单个的光学异构体可通过合适的方法由外消旋体得到,包括但不限于传统的方法,例如与光学活性酸成盐后再结晶。
本发明中的化合物,依次通过制备、分离纯化获得的该化合物其重量含量等于或大于90%,例如,等于或大于95%,等于或大于99%(“非常纯”的化合物),在正文描述列出。此处这种“非常纯”本发明的化合物也作为本发明的一部分。
本发明的化合物所有的构型异构体都在涵盖的范围之内,无论是混合物、纯的或非常纯的形式。在本发明化合物的定义包含顺式(Z)和返式(E)两种烯烃异构体,以及碳环和杂环的顺式和反式异构体。
在整个说明书中,基团和取代基可以被选择以提供稳定的片段和化合物。
本发明的某些化合物可能存在于特定的几何或立体异构体形式。本发明涵盖所有的化合物,包括其顺式和反式异构体、R和S对映异构体、非对映体、(D)型异构体、(L)型异构体、外消旋混合物和其它混合物。另外不对称碳原子可表示取代基,如烷基。所有异构体以及它们的混合物,都包涵在本发明中。
按照本发明,同分异构体的混合物含有异构体的比率可以是多样的。例如,在只有两个异构体的混合物可以有以下组合:50:50,60:40,70:30,80:20,90:10,95:5,96:4,97:3,98:2,99:1,或100:0,异构体的所有比率都在本发明范围之内。本专业内一般技术人员容易理解的类似的比率,及为更复杂的异构体的混合物的比率也在本发明范围之内。
本发明还包括同位素标记的化合物(也称为同位素化合物),等同于原始化合物在此公开。不过实际上对一个或更多的原子被与其原子量或质量序数不同的原子取代通常会出现。可以列为本发明的化合物同位素的例子包括氢,碳,氮,氧,磷,硫,氟和氯同位素,分别如
2H、
3H、
13C、
11C、
14C、
15N、
18O、
17O、
31P、
32P、
35S、
18F和
36Cl。本发明中的化合物,或对映体,非对映体,异构体,或药学上可接受的盐或溶剂化物,其中含有上述化合物的同位素或其他同位素原子都在本发明的范围之内。本发明中某些同位素标记化合物,例如
3H和
14C的放射性同位素也在其中,在药物和底物的组织分布实验中是有用的。氚,即
3H和碳-14,即
14C,它们的制备和检测比较容易。是同位素中的首选。此外,较重同位素取代如氘,即
2H,由于其很好的代谢稳定性在某些疗法中有优势,例如在体内增加半衰期或减少用量,因此,在某些情况下可以优先考虑。同位素标记的化合物可以用一般的方法,通过用易得的同位素标记试剂替换为非同位素的试剂,用批露在示例中的方案可以制备。
如果要设计一个本发明的化合物特定的对映体的合成,它可以不对称合成制备,或用手性辅剂衍生化,将所产生的非对映混合物分离,再除去手性辅剂而得到纯的对映体。另外,如果分子中含有一个碱性官能团,如氨基酸,或酸性官能团,如羧基,可以用合适的光学活性的酸或碱的与之形成非对映异构体盐,再通过分离结晶或色谱等常规手段分离,然后就得到了纯的对映体。
如本文所述,本发明中的化合物可与任何数量取代基或官能团取而扩大其包涵范围。通常,术语“取代”不论在术语“可选”前面或后面出现,在本发明配方中包括取代基的通式,是指用指定结构取代基,代替氢自由基。当特定结构中的多个在位置被多个特定的取代基取代时,取代基每一个位置可以是相同或不同。本文中所使用的术语“取代”包括所有允许有机化合物取代。从广义上讲,允许的取代基包括非环状的、环状的、支链的非支链的、碳环的和杂环的,芳环的和非芳环的有机化合物。在本发明中,如杂原子氮可以有氢取代基或任何允许的上文所述的有机化合物来补充其价态。此外,本发明是无意以任何方式 限制允许取代有机化合物。本发明认为取代基和可变基团的组合在以稳定化合物形式在疾病的治疗上是很好的。此处术语“稳定”是指具有稳定的化合物,在足够长的时间内检测足以维持化合物结构的完整性,最好是在足够长的时间内都在效,本文在此用于上述目的。
本申请所涉及的化合物及其药学可接受的盐的代谢产物,以及可以在体内转变为本申请所涉及的化合物及其药学可接受的盐的结构的前药,也包含在本申请的权利要求中。
制备方法
下面更具体地描述本发明式(I)结构化合物的制备方法,但这些具体方法不对本发明构成任何限制。本发明化合物还可以任选将在本说明书中描述的或本领域已知的各种合成方法组合起来而方便的制得,这样的组合可由本发明所属领域的技术人员容易的进行。
通常,在制备流程中,各反应通常惰性气体保护下,适当溶剂中,在室温到90℃下进行,反应时间通常为2-24小时。
方法一:
方法一中,R
1、R
2、R
3、R
4、R
5、R
6具有本发明所述的定义。所述方法包 括以下步骤:
(i)在有机溶剂如甲醇中,叠氮乙酸甲酯与化合物1-1中的醛基反应生成化合物1-2;优选地,所述反应在碱存在下进行,更优选地,所述碱为NaOMe(甲醇钠);
(ii)化合物1-2在有机溶剂如二甲苯中回流生成化合物1-3;
(iii)在惰性溶剂(如DMF)中,碱性条件下,化合物1-3与苄溴衍生物生成化合物1-4;优选地,所述反应在CsCO
3的存在下进行;
(iv)在有机溶剂(如甲醇和四氢呋喃的混合溶剂)中,碱性条件下,化合物1-4中的羧酸甲酯水解成羧酸生成化合物1-5;优选地,在LiOH的存在下水解;(v)在喹啉中,化合物1-5在酸性条件下与铜粉反应生成化合物1-6;优选地,在催化剂(如Cu)的存在下反应;
(vi)在有机溶剂(如DMSO和甲醇的混合溶剂)中,在碱性条件和一氧化碳的气氛下,化合物1-6经由钯催化生成化合物1-7;优选地,所用的钯催化剂为PdCl
2dppf,和/或反应的温度为75±5℃;
(vii)在有机溶剂(如甲醇和四氢呋喃的混合溶剂)中,碱性条件下,化合物7中的羧酸甲酯水解成羧酸生成化合物1-8;优选地,在LiOH的存在下水解;
(viii)在惰性溶剂(如DMF)中,化合物1-8与苄胺缩合生成化合物1-9;优选地,在HATU和DIEA的存在下缩合;
(ix)在惰性溶剂(如甲醇和四氢呋喃的混合溶剂)中,在碱性条件下,化合物1-9中的羧酸甲酯水解成羧酸生成化合物1-10;优选地,在LiOH的存在下水解。
以上反应步骤中,反应溶剂、反应温度、反应时间、催化剂等可以根据具体的反应物进行选择。
药物组合物和施用方法
由于本发明的化合物是优异的EP
4受体的拮抗剂,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物、溶剂合物、立体异构体、同位素化合物或前药等以及本发明所述的药物组合物可用于EP
4受体相关的疾病如前列腺素E
2/EP
4受体介导疾病的治疗或预防。本发明所述的药物组合物用于预防和/或治疗以下疾病:急性和慢性疼痛、炎性疼痛、与炎症相关联的疾患、骨关节炎和类风湿性关节炎、癌症的治疗中的用途。
本发明包括一种治疗对非甾体抗炎药敏感的炎性疾病的方法,该方法包括向需要这种治疗的患者施用无毒的治疗有效量的式I所示化合物。在该实施方案中包括以上方法,其中患者还处于血栓性心血管事件和/或胃肠道溃疡/出血的风险中。
本发明的另一个实施方案包括治疗前列腺素E2介导的疾病的方法,所述疾病有利地通过选择性拮抗EP
4的活性剂来治疗,而不是通过抑制COX-1/COX-2的活性剂来治疗,所述方法包括对需要这种治疗的患者施用无毒的有效量的式I所示化合物。在该实施方案中包括以上方法,其中患者也处于血栓性心血管事件的风险中。
举例来说,但不限于,本文所述的化合物可用于靶向肿瘤微环境中的宿主免疫抑制细胞的癌症免疫疗法,所述肿瘤微环境可以是髓系或淋巴系。在一个实施方案中,本文所述的化合物可用于治疗具有各种肿瘤类型的患者,包括那些具有高水平髓样浸润物的患者。可以例如基于癌症基因组图谱(TCGA)和其他来源来确定这种髓系浸润水平。还可以基于蛋白质或基因(例如,mRNA)表达分析来鉴定此类肿瘤类型。
肿瘤类型包括但不限于胰腺腺癌,肾透明细胞癌,头颈部鳞状细胞癌(SCCHN),非小细胞肺癌(NSCLC),结直肠癌(CRC),肝细胞癌(HCC),浆液性上皮性卵巢癌,宫颈癌,移行细胞膀胱癌,皮肤癌,成胶质细胞瘤,肾癌,前列腺癌。胰腺癌和三阴性乳腺癌(TNBC)。
本发明的化合物可用于在需要这种治疗或预防的受试者中治疗或预防肿瘤形成。治疗包括部分或全部抑制肿瘤形成,扩散或转移,以及部分或全部破坏肿瘤细胞。术语“预防”包括完全预防临床上明显的瘤形成的发作或预防处于危险中的个体的临床上明显的瘤形成阶段的发作。该定义还意图包括预防恶性细胞的起始或阻止或逆转恶性前细胞向恶性细胞的发展。这包括对有发生赘生物危险的人的预防性治疗。用于治疗目的的术语“受试者”包括患有任何一种已知肿瘤的任何人类或哺乳动物受试者,并且优选是人类受试者。对于预防方法,该受试者是任何人类或动物受试者,并且优选有患上肿瘤风险的人类受试者。受试者可能由于暴露于致癌剂,遗传易患肿瘤等,而处于危险中。
通式(I)所述化合物可以与已知的治疗或改进相似病状的其他药物联用。联合给药时,原来药物的给药方式和剂量可以保持不变,而同时或随后服用式I的化合物。当式I化合物与其它一种或几种药物同时服用时,可以优选使用同时 含有一种或几种已知药物和式I化合物的药用组合物。药物联用也包括在重叠的时间段服用式I化合物与其它一种或几种已知药物。当式I化合物与其它一种或几种药物进行药物联用时,式I化合物或已知药物的剂量可能比它们单独用药的剂量低。EP
4拮抗剂与以下药物的各种组合的抗肿瘤活性:辐射;细胞毒性t淋巴细胞抗原4的抗体(抗CTLA4);程序性死亡配体1的抗体(抗-PDL1);程序性细胞死亡蛋白1的抗体(抗PD1);并且已经检测到抗代谢物。本发明还包括一种用有效量的本发明化合物治疗癌症或使用有效量的本发明化合物与有效量的下述物质组合治疗癌症的方法:放射线;抗细胞毒性t淋巴细胞抗原4的抗体(抗CTLA4);抗程序性死亡配体1的抗体(抗PDL1);抗程序性细胞死亡蛋白1的抗体(抗PD1);吲哚胺-2,3-二加氧酶(IDO)抑制剂;色氨酸-2,3-双加氧酶(TDO)抑制剂;和抗代谢物。这些抗体可以选自但不限于MDX-010(ipilimumab,Bristol-Myers Squibb),CP-675,206(tremelimumab,Pfizer),MPDL 3280 A(Roche),MDX-1106(nivolumab,Bristol-MyersSquibb),labrolizumab(Merck)和pembrolizumab(Merck)。
“药学上可以接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如
)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
“药学上可接受的赋形剂”和“药学上可接受的载体”是指有助于活性剂的配制和/或施用和/或被个体吸收的物质,并且可以包含在本公开的组合物中而不引起对该个体的显著不利的毒理作用。药学上可接受的载体和赋形剂的非限制性实例包括水、NaCl、生理盐水溶液、乳酸林格氏液、常规蔗糖、常规葡萄糖、粘合剂、填充剂、崩解剂、润滑剂、包衣、甜味剂、风味剂、盐溶液(例如林格溶液)、醇、油、明胶、碳水化合物,诸如乳糖、直链淀粉或淀粉、脂肪酸酯、羟甲基纤维素、聚乙烯吡咯烷和颜料等。这样的制剂可以被灭菌,并且如果需要,与不会有害地与本文提供的化合物反应或干扰本文提供的化合物的活性的 辅助剂例如润滑剂、防腐剂、稳定剂、润湿剂、乳化剂、影响渗透压的盐、缓冲剂、着色剂和/或芳香物质等混合。本领域普通技术人员将认识到其他药物载体和赋形剂适用于公开的化合物。
在某些实施例中,本发明的药物组合物可以以固体或液体形式。
含有活性成分的药物(即式I所示化合物)可以是适宜的口服剂型,例如片剂,药片,含片,水溶性或油性悬液,分散乳胶粉或颗粒,乳剂,硬或软胶囊或糖浆或酏剂。口服使用的药物可根据药物成分制造商的已知工艺方法来制备,这些组合物可包括下述一种或多种药剂,例如甜味剂,调味剂,着色剂和保护剂,以便提供优雅和美味的药品制剂。药片含有与非毒性药学上可接受的赋形剂混合的活性成分,这些赋形剂适合于生产片剂。这些赋形剂的例子有,惰性稀释剂,例如碳酸钙、碳酸钠、乳糖、钙磷酸盐或磷酸钠;制粒,崩解剂,例如,玉米淀粉或褐藻酸;结合剂,例如如淀粉、明胶或阿拉伯胶,以及润滑剂,例如硬脂酸镁、硬脂酸或滑石粉。该药片可无涂层,也可有涂层,以延迟在胃肠道的降解和吸收,从而在较长时期内维持活性。
本发明的药物组合物可以通过胃肠外的、口服的、颊的、舌下的、鼻的、直肠的、局部的、或经皮的施用被施用。用于口服施用的药物组合物通常是优选的。
适合于口服施用的本发明的药物组合物典型地将是以固体形式的离散单元,例如以片剂、胶囊、扁囊剂、粉末、颗粒、锭剂、贴片、栓剂、丸剂的形式,或以液体形式,例如液体制剂、可注射的或可输注的溶液或悬浮液。
向个体提供治疗有效量的化合物的精确量将取决于给药方式、疾病和/或病症的类型和严重程度以及个体的特征,例如一般健康状况、年龄、性别、体重和对药物的耐受性。本领域普通技术人员将能够根据这些和其他因素确定合适的剂量。当与其他治疗剂组合施用时,任何其他治疗剂的“治疗有效量”将取决于所用药物的类型。合适的剂量对于批准的治疗剂是已知的,并且可以由本领域普通技术人员根据个体的状况、治疗的病症类型和通过以下使用的本发明化合物的量进行调整,例如,在文献中报道和在Physician’s Desk Reference(第57版,2003)中推荐的剂量。
本发明的药物组合物中,活性成分的含量通常为0.000001-1wt%,优选为0.00001-1wt%,最优选为0.0001-0.1wt%。
本发明的药物组合物或治疗剂的给药对象的实例包括哺乳动物(例如,人、 小鼠、大鼠、仓鼠、兔、猫、狗、牛、绵羊、猴等)。
本发明还提供了一种药物组合物的制备方法,包括步骤:将药学上可接受的载体与本发明所述通式(I)化合物或其晶型、药学上可接受的盐、水合物或溶剂合物进行混合,从而形成药物组合物。
本发明还提供了一种治疗方法,它包括步骤:给需要治疗的对象施用本发明中所述通式(I)化合物,或其晶型、药学上可接受的盐、水合物或溶剂合物,或施用本发明所述的药物组合物,用于选择性地抑制EP
4受体。
本发明具有以下主要优点:
(1)本发明化合物对EP
4受体具有优良的抑制活性,且对EP
4受体具有更好的选择抑制活性;
(2)本发明化合物具有更低的毒副作用;
(3)本发明化合物具有更好的药效学、药代动力学性能及成药性。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件如Sambrook等人,分子克隆:实验室手册(New York:Cold Spring Harbor Laboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
本发明的化合物结构是通过核磁共振(NMR)和液质联用色谱(LC-MS)来确定的。
NMR是使用Bruker AVANCE-400和Bruker AVANCE-500核磁仪检测的,测定溶剂包含氘代二甲亚砜(DMSO-d
6)、氘代丙酮(CD
3COCD
3)、氘代氯仿(CDCl
3)及氘代甲醇(CD
3OD)等,内标采用四甲基硅烷(TMS),化学位移以百万分之一(ppm)的单位计量。
液质联用色谱(LC-MS)是使用Agilent 1260质谱仪检测的。HPLC的测定使用Agilent 1100高压色谱仪(Microsorb 5micron C18 100x3.0mm色谱柱)。
薄层层析硅胶板使用青岛GF254硅胶板,TLC采用的是0.15-0.20mm,制备薄 层色谱采用的是0.4mm-0.5mm。柱层析一般使用青岛硅胶200-300目硅胶作为载体。
本发明实施例中的起始原料都是已知并有市售的,或者可以采用或按照本领域已报道的文献资料合成的。
除特殊说明外,本发明所有反应均在干燥的惰性气体(如氮气或氩气)保护下通过连续磁力搅拌进行,反应温度均为摄氏度。
下列简写词的使用贯穿本发明
THF:四氢呋喃;MeOH:甲醇;HCl:盐酸;Pd(PPh
3)
4:四三苯基膦钯;K
2CO
3:碳酸钾;AcOK:醋酸钾;NaOH:氢氧化钠;H
2O:水;TEA:三乙胺;DIEA:N,N-二异丙基乙胺;DMF:N,N-二甲基甲酰胺;DMA:N,N-二甲基乙酰胺;Py:吡啶;DCE:1,2-二氯乙烷;DMSO:二甲基亚砜;TFA:三氟乙酸;NaBH(AcO)
3:三乙酰基硼氢化钠;Sn
2(Bu-n)
6:六己基二锡;AlCl
3:三氯化铝;CuI:碘化亚铜;DPPA:叠氮磷酸二苯酯;BuOH:叔丁醇;Cs
2CO
3:碳酸铯;K
3PO
4:磷酸钾;BnBr:苄溴;Pd
2(dba)
3:三(二亚苄基丙酮)二钯;X-Phos:2-二环己基磷-2,4,6-三异丙基联苯;EA:乙酸乙酯;NaHCO
3:碳酸氢钠;DIPEA:N,N-二异丙基乙胺;HBr:溴化氢;
实施例
实施例1 化合物1的合成
步骤1:合成2-叠氮-3-(4-溴-5-甲基噻吩-2-基)丙烯酸甲酯
将叠氮醋酸甲酯(8.3g,72.8mmol),4-溴-5-甲基噻吩-2-甲醛(5g,24mmol)溶于50mL甲醇,在-25℃下,滴加NaOMe的甲醇溶液(13.5mL,5.4M)。在0℃搅拌2h,加入50mL冰水。搅拌过滤,滤饼经水洗涤,干燥。得2-叠氮-3-(4-溴-5-甲基噻吩-2-基)丙烯酸甲酯(3.6g,49%),不需纯化并可用于下一步。
步骤2:合成3-溴-2-甲基-4H-噻吩[3,2-b]吡咯-5-羧酸甲酯
10分钟内,向回流二甲苯(40mL)中滴加溶于二甲苯(50mL)溶解的上一步粗产物(3.6g)。回流20分钟后,冷却到室温,浓缩移除溶剂得到固体粗产物。固体经溶解,萃取,干燥,浓缩得3-溴-2-甲基-4H-噻吩[3,2-b]吡咯-5-羧酸甲酯(3.2g,98%),MS:m/z(ESI):273.95[M+H]
+。
步骤3:合成3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯
将3-溴-2-甲基-4H-噻吩[3,2-b]吡咯-5-羧酸甲酯(2.5g,9.1mmol)、4-(五氟硫基)苄基溴(3.0g,10.1mmol)、碳酸铯(9.0g,27.5mmol)溶解在DMF(20mL)中,在室温搅拌4小时。反应完全后加水淬灭,分离有机相,水洗,干燥,经柱层析(PE:EA=5:1)得到3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯(3.0g,90%)黄色固体。MS:m/z(ESI):489.95[M+H]
+。
步骤4:合成3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩并[3,2-b]吡咯-5-羧酸
室温下,将3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯(3.0g,6.1mmol)溶于1:1的MeOH/THF的(40mL),然后加入H
2O(20mL),氢氧化锂(404mg,18.4mmol),55℃搅拌反应2小时,浓缩移除有机溶剂,柠檬酸水溶液调节PH=4-5,固体过滤,洗涤干燥得3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-5-羧酸(3.0g)黄色固体。MS:m/z(ESI):475.93[M+H]
+。
步骤5:合成3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯
将3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-5-羧酸(3.0g,6.3mmol)溶于30mL喹啉,然后加入2.0g铜粉,140℃反应16小时。冷却到室温,加入6N盐酸酸化至酸性,经萃取,水洗,干燥,柱层析(PE)得到3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯(1.21g,44%)浅黄色固体。MS m/z(ESI):431.94[M+H]
+。
步骤6:合成2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羧酸甲酯
室温下,将3-溴-2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯(0.7g,1.85mmol)、PdCl
2dppf.CH
2Cl
2(680mg,0.83mmol)、三乙胺(374mg,3.70mmol)溶于20毫升1:1的二甲基亚砜/甲醇,在CO(气球压力)中,75℃下加热过夜。反应完全后加水淬灭、萃取、水洗、干燥,柱层析(PE:EA=2:1)得到2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羧酸甲酯(0.4g,52%)黄色固体。MS m/z(ESI):412.04[M+H]
+。
步骤7:合成2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羧酸
室温下,将2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羧酸甲酯(0.4g,0.97mmol)溶于1:2的MeOH/THF的(15mL),然后加入H
2O(5mL),氢氧化锂(116mg,0.85mmol),55℃搅拌反应2小时,浓缩移除有机溶剂,柠檬酸水溶液调节PH=4-5,固体过滤,洗涤干燥得2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羧酸(340mg,85%)黄色固体。MS m/z(ESI):398.1[M+H]
+。
步骤8:合成4-(1-{[2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羰基]氨基}-环丙基)苯甲酸甲酯
室温下,将2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羧酸(340mg,0.85mmol),4-(1-氨基环丙基)-苯甲酸甲酯(245mg,1.28mmol)、HATU(486mg,1.28mmol)和DIEA(220mg,1.7mmol)溶于DMF(10mL),室温下搅拌16小时。反应完全加水淬灭、萃取、水洗、干燥,柱层析(DCM:MeOH=20:1)得到4-(1-{[2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羰基]氨基}-环丙基)苯甲酸甲酯(0.45g,92%)黄色固体。MS m/z(ESI):571.1[M+H]
+。
步骤9:合成4-(1-{[2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羰基]氨基}-环丙基)苯甲酸
室温下,4-(1-{[2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羰基]氨基}-环丙基)苯甲酸甲酯(0.45g,0.79mmol)溶于1:2的MeOH/THF的(30mL),然后加入H
2O(5mL),氢氧化锂(190mg,7.91mmol),55℃搅拌反应2小时,浓缩移除有机溶剂,柠檬酸水溶液调节pH 4-5,固体过滤,洗涤干燥得粗品,粗品用乙醚(10mL)打浆得4-(1-{[2-甲基-4-(4-(五氟硫基)苄基)-4H-噻吩[3,2-b]吡咯-3-羰基]氨基}-环丙基)苯甲酸(化合物1)(340mg,85%)黄色固体。MS m/z(ESI):557.1[M+H]
+。
1H NMR(400MHz):δ11.12(s,1H),8.98(s,1H),7.69-7.74(m,4H),7.14(d,2H),7.06(s,1H),6.97(d,2H),6.38(s,2H),5.43(s,2H),2.48(s,3H),1.17(m,2H), 0.96(m,2H)。
实施例2
以与实施例1类似的方法制备表1中的其他化合物。
生物活性测试例1:
(a)放射性配体EP4受体结合测定:
实验方法:用试验缓冲液(1X HBSS+20mM HEPES+0.1%BSA+500μM IBMX)将Flpin-CHO-EP4细胞(8000个/孔)种入384孔板(6007680-50,PE)。用试验缓冲液配制8X化合物工作液。按照plate map在细胞板中每孔加入2.5μL 8×化合物工作液,37℃孵育10min。用试验缓冲液制备8X PGE2(400nM)。在细胞板中每孔加入2.5μL 8 X PGE2,37℃孵育30分钟。用裂解缓冲液稀释Eu-cAMP示踪剂(1/50),每孔加入10μl至检测板。用裂解缓冲液稀释Ulight-anti-cAMP(1/150),每孔加入10μl至检测板。室温孵育1h。在Envision 2105读板器上读取665nm和615nm波长信号值。结果如表2.
表2:
经测试,本发明的化合物具有优异的EP4受体的结合活性,具有优异的EP
4受体抑制能力。
(b)本发明化合物的PK的确定:
在雄性Han Wistar大鼠中研究化合物的药物动力学。使用静脉内注射以及口服的方式给药(对于每个剂量途径n=3),在给药后的多个时间点进行取样。使用特异性的并且灵敏的LC-MS/MS生物分析方法定量地分析血浆抽出物。
经测试,本发明的化合物具有较好的药效学、药代动力学性能。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (10)
- 一种式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药;其中,R 1独立地选自下组:氢、卤素、取代或未取代的C 1-6烷基、取代或未取代的C 3-6环烷基;R 2和R 3各自独立选自下组:氢、取代或未取代的C 1-6烷基、取代或未取代的C 3-6环烷基;或者,R 2和R 3以及与其相连的碳原子共同构成C 3-6碳环或3至6元杂环;所述杂环包含一个或两个各独立选自S、O或NR b的环成员;并且,所述C 3-6碳环或3至6元杂环任选地被一个或多个R 1取代;R b各自独立地选自下组:氢、取代或未取代的C 1-6烷基、取代或未取代的C 3-6环烷基、取代或未取代的C 6-10芳基、取代或未取代的5至6元杂芳基、-C(O)R c、-S(O) 2R c;R c各自独立地选自下组:取代或未取代的C 1-6烷基、取代或未取代的C 3-6碳环、取代或未取代的3至6元杂环、取代或未取代的C 6-10芳基、取代或未取代的5至10元杂芳基;R 4和R 5各自独立选自下组:氢、取代或未取代的C 1-3烷基;或者,R 4和R 5以及与其相连的碳原子共同构成取代或未取代的C 3-6碳环;R 6代表无或选自下组的基团:卤素、氰基、卤代烷基;除非特别说明,所述的取代是指基团中一个或多个氢被选自下组的取代基所取代:卤素、C 1-4烷基、C 1-4卤代烷基。
- 如权利要求1所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,其特征在于,R 1独立地选自下组:氢、卤素、C 1-6烷基、C 3-6环烷基、C 3-6氟代环烷基、C 1-6氟代烷基;R 2和R 3各自独立选自下组:氢、C 1-6烷基、C 3-6环烷基、C 3-6氟代环烷基、C 1-6氟代烷基;或者,R 2和R 3以及与其相连的碳原子一起共同构成C 3-6元碳环或3至6元杂环;其中,所述杂环包含一个或两个各独立选自S、O或NR b的环成员;并且,所述C 3-6碳环或3至6元杂环还任选地被R 1取代;R b选自下组:氢、C 1-6烷基、C 3-6环烷基、C 3-6氟代环烷基、C 1-6氟代烷基、C 6-10芳基、5至10元杂芳基、C(O)-C 1-6烷基、C(O)-C 6-10芳基、S(O) 2-C 1-6烷基、S(O) 2-C 6-10芳基;R 4和R 5各自独立为氢或C 1-3烷基;R 6代表无或选自下组的取代基:卤素、氰基、三氟甲基。
- 如权利要求1或2所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,其特征在于,R 1选自下组:氢、卤素、C 1-6烷基、C 3-6环烷基。
- 如权利要求1或2所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,其特征在于,R 2和R 3各自独立地选自氢、C 1-6烷基;或者,R 2和R 3以及与其相连的碳原子共同构成环丙基。
- 如权利要求1或2所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,其特征在于,R 4和R 5各自独立地为氢或甲基。
- 如权利要求1或2所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,其特征在于,R 6代表无或卤素。
- 如权利要求1或2所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,其特征在于,所述化合物选自下组:
- 一种药物组合物,其包含如权利要求1-7任一所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药,以及药学上可 接受的载体或稀释剂。
- 一种如权利要求1至7中任一所述的式I化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、同位素化合物或前药或如权利要求8所述的药物组合物在制备(i)用于抑制EP 4受体的药物和/或(ii)用于治疗或预防与EP 4受体相关疾病的药物和/或(iii)EP 4受体拮抗剂中的用途。
- 如权利要求9所述的用途,其特征在于,所述EP 4受体相关疾病包括:急性和慢性疼痛、骨关节炎、类风湿关节炎、癌症,或其组合。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021101185861 | 2021-01-28 | ||
CN202110118586 | 2021-01-28 | ||
PCT/CN2022/074184 WO2022161422A1 (zh) | 2021-01-28 | 2022-01-27 | 杂环酰胺衍生物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116783201A true CN116783201A (zh) | 2023-09-19 |
Family
ID=82652999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280012166.8A Pending CN116783201A (zh) | 2021-01-28 | 2022-01-27 | 杂环酰胺衍生物及其制备方法和应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230399339A1 (zh) |
EP (1) | EP4286390A1 (zh) |
CN (1) | CN116783201A (zh) |
TW (1) | TW202241909A (zh) |
WO (1) | WO2022161422A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024041559A1 (en) * | 2022-08-24 | 2024-02-29 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic compounds as ep4 receptor antagonists |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010019796A1 (en) * | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
CA3090485C (en) * | 2018-02-05 | 2024-01-16 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
CN111936502B (zh) * | 2018-03-02 | 2024-05-31 | 深圳市原力生命科学有限公司 | 杂二环羧酸及其盐 |
-
2022
- 2022-01-27 US US18/274,548 patent/US20230399339A1/en active Pending
- 2022-01-27 CN CN202280012166.8A patent/CN116783201A/zh active Pending
- 2022-01-27 WO PCT/CN2022/074184 patent/WO2022161422A1/zh active Application Filing
- 2022-01-27 EP EP22745295.0A patent/EP4286390A1/en active Pending
- 2022-01-27 TW TW111103715A patent/TW202241909A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022161422A1 (zh) | 2022-08-04 |
US20230399339A1 (en) | 2023-12-14 |
EP4286390A1 (en) | 2023-12-06 |
TW202241909A (zh) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102520543B1 (ko) | 피리딘 화합물 | |
TW202128691A (zh) | Kras 突變蛋白抑制劑 | |
KR102438340B1 (ko) | 인간 히스톤 메틸트랜스퍼라제 ezh2 억제제의 염 형태 | |
JP2021519282A (ja) | HIF−2−αの阻害薬による消化器系の炎症軽減方法 | |
WO2021213317A1 (zh) | Hpk1抑制剂及其制备方法和用途 | |
EP4043450A1 (en) | 2h-benzopyran derivatives as crac inhibitors | |
CN116390728B (zh) | 喹唑啉衍生物及其制备方法和用途 | |
WO2023098426A1 (zh) | 一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用 | |
US9724331B2 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
JP6666458B2 (ja) | 置換のアミノ6員窒素含有複素環式化合物およびその製造と使用 | |
JP7245918B2 (ja) | サルササポゲニン構造に基づく誘導体、医薬組成物及びその使用 | |
EP4286371A1 (en) | Pyrazolamide derivative, preparation method therefor, and application thereof | |
CN116783201A (zh) | 杂环酰胺衍生物及其制备方法和应用 | |
EA027882B1 (ru) | Этинильные производные в качестве антагонистов метаботропного глутаматного рецептора | |
CN106317057A (zh) | 具有咪唑并吡嗪类衍生物,其制备及其在医药上的应用 | |
TWI828289B (zh) | 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法 | |
EP3242881B1 (en) | Furoquinolinediones as inhibitors of tdp2 | |
JP2022527279A (ja) | キノリン誘導体及び癌の治療のためのその使用 | |
RU2810215C2 (ru) | Ингибиторы рецепторов erbb | |
CN115974855A (zh) | Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途 | |
EP4397660A1 (en) | Compound as tyk2/jak1 pseudokinase domain inhibitor, and synthesis and use methods | |
WO2023083373A1 (zh) | 作为Src抑制剂的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |